doi: 10.1016/j.biocel.2016.07.017 41
TRIUMPH-1 through TRIUMPH-4 focus on core efficacy and safety endpoints across different patient populations, while TRIUMPH-OUTCOMES specifically addresses cardiovascular safety and efficacya critical requirement for obesity medications given the cardiovascular risks associated with obesity itself [25]
Bajramagic S, Sever M, Rasic F, Staresinic M, Skrtic A, Beketic Oreskovic L, et al
RS5 RS5 is an amylose-lipid complex formed by combining amylose with fatty acids or fatty alcohols
'If you find something, it will take many years and lots of money to get something that is approved as a drug to use on humans.' Exenatide (commercial name Byetta), the synthetic version of exendin-4, was developed in 1992 but was not approved for use until 2005
ShedRx is not the right choice if you need to use insurance to cover GLP-1 medications